跳至主要内容
临床试验/NCT05873348
NCT05873348已完成不适用

A Controlled Study on Regulation of Systemic Inflammation by Fecal Bacteria Transplantation in Patients With COVID-19.

Shanghai 10th People's Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年1月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Changes of inflammatory factors in the two groups

研究概览

简要总结

A total of 30 hospitalized patients with COVID-19 over 60 years old were enrolled in this study and were divided into the experimental group (n=15) and the control group (n=15) at a ratio of 1:1. Both groups were treated according to the 2022 Shanghai guidelines for Diagnosis and Treatment of COVID-19 infection and the hierarchical diagnosis and treatment process. The experimental group was treated with fecal microbiota transplantation (FMT) capsules for 1 week, and the control group was treated with empty capsules. Patients in both groups were followed up for 1 month after discharge. To observe the effect of combined FMT capsule treatment on the regulation of inflammatory factors in peripheral blood and the remodeling of intestinal flora, and to verify its safety.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
60 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Over 60 years old, male or female;
  • •Meet the diagnostic criteria of COVID-19;
  • •The patient signed the informed consent, agreed to receive FMT capsule treatment, agreed to cooperate with the whole process of the clinical trial, and agreed to collect clinical data and blood, saliva, urine, stool and other samples;
  • •The patient was able to swallow 3# capsules by herself.

排除标准

  • •Confirmed diagnosis of non-COVID19 pneumonia;
  • •Critically ill patients requiring mechanical ventilation, or patients who are unable to eat by mouth and swallow 3# capsules;
  • •Patients who had undergone gastrointestinal surgery;
  • •Presence of intestinal organic lesions such as congenital megacolon, intestinal obstruction, intussusception, etc.
  • •Pathological intestinal inflammatory changes, such as inflammatory bowel disease;
  • •Planned use of antacids, probiotics, antibiotics, FMT and other treatments affecting intestinal flora within the past 3 months or the following 2 months;
  • •Patients and their families did not agree to receive FMT treatment;
  • •Patients unable to cooperate with follow-up visits.

研究组 & 干预措施

FMTgroup

Experimental

干预措施: Fecal microbiota transplantation (Procedure)

control gtoup

No Intervention

结局指标

主要结局

Changes of inflammatory factors in the two groups

时间窗: 7day,1month

The changes of inflammatory factors in the transplantation group were detected compared with the control group

次要结局

未报告次要终点

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Huanlong Qin

chief physician

Shanghai 10th People's Hospital

研究点 (1)

Loading locations...

相似试验